List of Excipients in Branded Drug CLARITIN-D

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bayer HealthCare LLC	CLARITIN-D	loratadine and pseudoephedrine sulfate	11523-4332	CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE
Bayer HealthCare LLC	CLARITIN-D	loratadine and pseudoephedrine sulfate	11523-4332	CARNAUBA WAX
Bayer HealthCare LLC	CLARITIN-D	loratadine and pseudoephedrine sulfate	11523-4332	ETHYLCELLULOSES

Generic Drugs Containing CLARITIN-D

Company	Ingredient	NDC	Excipient
Bayer HealthCare LLC	loratadine pseudoephedrine sulfate	11523-0102	CANDELILLA WAX
Bayer HealthCare LLC	loratadine pseudoephedrine sulfate	11523-0102	ETHYLCELLULOSES
Bayer HealthCare LLC	loratadine pseudoephedrine sulfate	11523-0102	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in CLARITIN-D?

# Of NDCs	Excipient
1	CANDELILLA WAX
1	ETHYLCELLULOSES
1	FERROSOFERRIC OXIDE

CLARITIN-D Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

CLARITIN-D combines loratadine, a second-generation antihistamine, with pseudoephedrine sulfate, an oral nasal decongestant. Its commercial differentiation depends less on active-ingredient exclusivity than on controlled-release performance, tablet robustness, pharmacy-channel access, compliant pseudoephedrine distribution, and brand recognition. The main product opportunities are authorized-generic supply, private-label extended-release tablets, excipient optimization, packaging compliance, and alternative delivery formats that preserve decongestant control requirements.

What is CLARITIN-D and how is it formulated?

CLARITIN-D is an extended-release combination product sold in two principal strengths:

Product	Loratadine	Pseudoephedrine sulfate	Dosing interval	Dosage form
CLARITIN-D 12 Hour	5 mg	120 mg	Every 12 hours	Extended-release tablet
CLARITIN-D 24 Hour	10 mg	240 mg	Every 24 hours	Extended-release tablet

The pseudoephedrine quantities correspond to the labeled pseudoephedrine base content. Both products are oral, swallowable, extended-release tablets. The dosage form is designed to provide antihistamine activity while sustaining decongestant exposure over the labeled interval. FDA labeling instructs patients not to crush, chew, or break the tablets because that can affect modified release [1,2].

The product is not a biologic and has no biosimilar pathway. Competitive entry occurs through abbreviated new drug applications, OTC regulatory pathways where applicable, private-label arrangements, or other FDA-approved routes for combination drug products.

What excipients are used in CLARITIN-D tablets?

Public FDA labeling identifies excipient classes and inactive ingredients, but the commercial formulation and manufacturing process may include proprietary specifications that are not fully disclosed in consumer-facing materials.

Reported inactive ingredients for CLARITIN-D products include excipients commonly used in compressed extended-release tablets:

• Lactose monohydrate as a diluent
• Corn starch as a filler or processing aid
• Crospovidone as a disintegrant
• Povidone as a binder
• Magnesium stearate as a lubricant
• Colloidal silicon dioxide as a glidant
• Stearic acid as a lubricant or processing aid
• Coating materials, including film-forming polymers and colorants, depending on the product presentation

The exact excipient list should be confirmed against the current FDA-approved labeling for each strength and manufacturer. A formulation change can require regulatory review even when the active ingredients and labeled strength remain unchanged.

What does each excipient contribute?

Excipient function	Commercial purpose in an extended-release tablet
Diluent	Provides tablet mass and supports content uniformity
Binder	Improves granule and tablet mechanical strength
Disintegrant	Controls breakup of the immediate-release component
Lubricant	Reduces ejection force and tooling friction
Glidant	Improves powder flow and die filling
Release-control polymer	Limits pseudoephedrine release over 12 or 24 hours
Coating system	Protects the tablet, supports identification, and can influence moisture uptake
Opacifier or colorant	Provides visual differentiation and brand or private-label identification

The central formulation problem is balancing rapid availability of loratadine with sustained delivery of pseudoephedrine. A conventional immediate-release formulation would not reproduce the labeled 12-hour or 24-hour profile. The excipient system therefore has a direct impact on bioavailability, dose dumping risk, tablet integrity, and regulatory comparability.

What excipient strategy protects CLARITIN-D performance?

Controlled release is the primary technical barrier

The most valuable formulation knowledge is likely embedded in the extended-release architecture rather than in the identity of common excipients. A developer may use a hydrophilic matrix, coated granules, multilayer compression, or a combination of immediate-release and sustained-release components. The commercial objective is to control pseudoephedrine dissolution while maintaining acceptable loratadine release.

Important development variables include:

• Polymer type and viscosity grade
• Polymer concentration and distribution
• Granule size and porosity
• Compression force and tablet hardness
• Lubricant concentration
• Coating weight gain
• Moisture content
• Storage humidity
• API particle size and polymorphic form
• Dissolution performance across pH conditions
• Food-effect behavior

A formulation that passes a single dissolution condition may still fail under broader development testing. Extended-release combination products require testing across multiple media, agitation conditions, tablet orientations, and dose-dumping challenges.

Excipient compatibility is important for both APIs

Loratadine is poorly water soluble, while pseudoephedrine sulfate is highly water soluble. Their different solubility and release characteristics create a formulation-management problem. A matrix that controls pseudoephedrine too aggressively may delay or impair the product’s decongestant effect. A matrix that releases pseudoephedrine too quickly may compromise the extended-release profile.

Compatibility screening should examine:

• API-excipient chemical interaction
• Moisture sensitivity
• Thermal stability
• Compression-induced degradation
• Dissolution drift during accelerated stability
• Color and odor changes
• Residual solvent and volatile content
• Extractables and leachables from packaging

Lactose-containing formulations also require assessment of potential compatibility with amine-containing drug substances. The development team should evaluate Maillard-type reactions and related degradation pathways rather than assuming that lactose is risk-free in a solid oral combination.

What formulation patents protect CLARITIN-D?

The commercial protection for CLARITIN-D historically could include patents directed to:

1. Loratadine and pseudoephedrine combinations.
2. Sustained-release delivery of pseudoephedrine.
3. Specific tablet structures or release-control matrices.
4. Particle-size distributions and granulation methods.
5. Coated particles or multiparticulate systems.
6. Methods for treating allergic rhinitis and nasal congestion.
7. Manufacturing processes and quality-control specifications.

The core active-ingredient patents for loratadine and pseudoephedrine are no longer the principal barrier to entry. The practical question is whether any enforceable formulation, method-of-use, or manufacturing claims remain relevant to a particular generic product.

The FDA Orange Book is the primary source for checking listed patents and regulatory exclusivity associated with an NDA product [3]. A patent listed for a product does not automatically prevent all generic entry. The scope depends on the claim language, the proposed generic’s formulation, and the applicant’s certification and litigation position.

What is the Orange Book status of CLARITIN-D?

CLARITIN-D is an FDA-approved combination drug product, and Orange Book review is relevant for assessing listed patents, therapeutic-equivalence codes, and reference-product status. The applicable NDA and product-specific listings should be checked separately for the 12-hour and 24-hour strengths because they may have different regulatory histories and product identifiers.

The commercial analysis should distinguish:

• Approved NDA products
• Abbreviated new drug applications
• Authorized generics
• OTC monograph products
• Behind-the-counter distribution
• National Drug Code listings
• Therapeutic-equivalence ratings
• Listed patents and exclusivity codes

CLARITIN-D does not have biologic exclusivity, interchangeable-biologic issues, or biosimilar exposure. Its relevant competitors are generic extended-release loratadine-pseudoephedrine products and alternative allergy-decongestant combinations.

When does CLARITIN-D lose exclusivity?

The original chemical and product exclusivity periods for a product first approved in the 1990s have expired. CLARITIN-D therefore competes in a mature market where the remaining commercial protection is based primarily on brand equity, retail placement, formulation execution, supply reliability, and regulatory compliance.

A current exclusivity assessment should separate four concepts:

Exclusivity category	Relevance to CLARITIN-D
New chemical entity exclusivity	Expired for the mature active ingredients
Five-year orphan or pediatric exclusivity	Not a central protection mechanism for this product
Patent exclusivity	Must be checked by product and current Orange Book listing
Trade dress and trademark protection	Can remain commercially important after patent expiry

Trademark and trade-dress protection can restrict copying of brand identifiers, packaging presentation, and consumer-facing claims. Those rights do not prevent a generic from selling a therapeutically equivalent product under a different name.

Which companies are challenging CLARITIN-D?

Generic-drug manufacturers and private-label suppliers are the principal commercial challengers. The market has included products labeled with combinations such as loratadine and pseudoephedrine sulfate in 12-hour and 24-hour extended-release formats.

Potential competitors fall into four groups:

• Large generic manufacturers with FDA-approved extended-release capabilities
• Contract manufacturers supplying retailer private labels
• Regional manufacturers serving pharmacy and grocery channels
• Brand and store-brand allergy portfolios that compete through alternative dosage forms

A complete company-by-company challenge table requires current FDA approval and marketing data. The commercially relevant point is that competition does not depend on a single Paragraph IV event. Multiple manufacturers can enter after patent and regulatory barriers decline, particularly where the reference product has high retail demand.

What Paragraph IV risks affect CLARITIN-D?

Paragraph IV litigation is relevant only when a generic applicant certifies that a listed patent is invalid, unenforceable, or not infringed. If no relevant patent remains listed, an applicant may use another certification pathway.

For CLARITIN-D, the major historical risk would have involved patents covering extended-release combination tablets or methods of treating allergy symptoms and congestion. A generic applicant can reduce exposure by:

• Designing around release-control claims
• Using a different polymer or tablet architecture
• Avoiding a patented manufacturing step
• Omitting a patented method-of-use indication where permitted
• Filing a Paragraph IV certification against a listed patent
• Seeking a declaratory judgment or negotiating a settlement

A formulation patent is strongest when its claims capture a measurable release profile, a narrow structural arrangement, or a difficult-to-replicate manufacturing step. It is weaker when it claims broad use of familiar excipients without a demonstrated technical effect.

How strong is the CLARITIN-D patent estate?

The current strategic strength of the CLARITIN-D estate is likely lower than the product’s brand strength. Mature active ingredients and long commercial exposure reduce the probability that broad composition claims remain enforceable. Any residual strength would be concentrated in narrow formulation or manufacturing claims.

Patent category	Expected strategic strength
Broad loratadine composition claims	Low after expiry
Broad pseudoephedrine composition claims	Low after expiry
Combination-use claims	Low to moderate, depending on claim scope
Extended-release matrix claims	Moderate if narrowly drafted and technically supported
Coated-particle or multilayer claims	Moderate to high if difficult to design around
Manufacturing-process claims	Variable; often difficult to detect in a competitor’s product
Packaging or trade dress	Commercially relevant but not a substitute for patent exclusivity

Patent value also depends on enforcement economics. A low-margin OTC product may not justify prolonged litigation unless the brand has substantial sales or the patent covers a large portfolio of products.

What commercial opportunities exist for CLARITIN-D excipients?

1. Authorized-generic and private-label supply

The largest opportunity is supplying compliant extended-release tablets to pharmacy chains, mass retailers, grocery retailers, and e-commerce distributors. Buyers typically value:

• FDA approval history
• Consistent dissolution performance
• Reliable pseudoephedrine supply
• Competitive cost per tablet
• Low complaint and recall rates
• Packaging that supports pharmacy controls
• Capacity during seasonal allergy peaks

2. Direct compression and continuous manufacturing

A manufacturer may reduce cost through direct compression if powder flow, content uniformity, and release control are adequate. Continuous manufacturing could improve lot consistency and reduce inventory, but the process must demonstrate control of API segregation, compression variability, and coating or matrix uniformity.

3. Excipient substitution

Excipient suppliers can target lactose-reduced, lactose-free, low-moisture, or low-dust platforms. The strongest opportunity is not simply replacing one common excipient with another. It is showing that the replacement improves stability, manufacturability, dissolution robustness, or patient acceptability without changing the approved performance profile.

Potential development platforms include:

• Coprocessed fillers for improved flow
• High-functionality binders for lower compression force
• Polymer systems with less dissolution variability
• Low-moisture excipients for improved stability
• Lubricant systems that reduce hydrophobic dissolution effects
• Film coatings with improved moisture protection

Any substitution that changes dissolution or bioavailability may require comparative regulatory work.

4. Packaging and pseudoephedrine compliance

Pseudoephedrine products are subject to federal retail-sale restrictions and purchase-quantity controls under the Combat Methamphetamine Epidemic Act [4]. Packaging is therefore a material commercial issue.

Opportunities include:

• Unit-dose blister packs
• Tamper-evident cartons
• Serialized packaging
• Pharmacy inventory controls
• Packaging that limits accidental dose duplication
• Designs optimized for behind-the-counter storage
• Consumer instructions that reduce misuse and improper tablet manipulation

Packaging cannot eliminate legal retail restrictions, but it can reduce operational friction and improve inventory control.

What generic launch scenarios exist for CLARITIN-D?

Scenario 1: Standard generic entry

A manufacturer launches an FDA-approved extended-release equivalent after resolving listed-patent and regulatory issues. Competition focuses on wholesale price, retailer contracts, and supply reliability.

Scenario 2: Private-label substitution

A retailer replaces or supplements branded CLARITIN-D with a store-brand equivalent. This scenario can pressure brand pricing even without a large number of independent generic manufacturers.

Scenario 3: Limited seasonal launch

A supplier enters before the spring or fall allergy season with constrained inventory. Seasonal demand creates an opportunity for premium supply contracts but increases the risk of stockouts and quality deviations.

Scenario 4: Formulation redesign

A company develops a different extended-release architecture that avoids residual formulation claims. The primary risk is proving comparable release and therapeutic performance.

Scenario 5: Channel-specific products

A supplier offers different pack sizes or packaging configurations for pharmacies, warehouse clubs, grocery retailers, and online channels. The active ingredients remain unchanged, but packaging economics and pseudoephedrine controls differ.

How does CLARITIN-D compare with competing allergy products?

Product category	Main active ingredients	Decongestant included	Release strategy	Main commercial advantage
CLARITIN-D	Loratadine plus pseudoephedrine	Yes	Extended release	Established brand and long dosing interval
Plain loratadine	Loratadine	No	Immediate or standard oral release	No pseudoephedrine restrictions
Cetirizine products	Cetirizine	Usually no	Standard oral release	Broad generic availability
Fexofenadine products	Fexofenadine	Usually no	Standard oral release	Non-sedating positioning
Other antihistamine-decongestant combinations	Varies	Yes	Immediate or extended release	Alternative price and channel positioning

CLARITIN-D’s main differentiation is the inclusion of pseudoephedrine. That creates stronger decongestant positioning but also creates retail restrictions, supply-chain controls, and greater regulatory complexity than plain antihistamine products.

What FDA regulatory issues affect CLARITIN-D?

FDA considerations include:

• Extended-release dissolution specifications
• Bioequivalence or comparative performance
• Combination-product labeling
• Manufacturing-process validation
• Stability under climatic conditions
• Tablet integrity and dose-dumping risk
• Inactive-ingredient changes
• Pseudoephedrine retail controls
• Labeling for contraindications and drug interactions
• Packaging and child-resistance requirements where applicable

FDA labeling warns about hypertension, cardiovascular disease, thyroid disease, diabetes, glaucoma, urinary retention, and monoamine oxidase inhibitor interactions. These warnings affect consumer communication and product positioning [1,2].

What revenue exposure does CLARITIN-D create?

Public revenue attribution for CLARITIN-D alone is generally less transparent than company-wide consumer-health revenue. The relevant exposure is driven by:

• Spring and fall allergy seasons
• Retailer shelf placement
• Price gaps between brand and store brand
• Availability of pseudoephedrine
• Consumer migration to plain antihistamines
• Generic substitution
• Stockout frequency
• Promotional spending
• Regulatory or supply interruptions

The brand is more exposed to erosion in unit volume and price than to complete market disappearance. Pseudoephedrine restrictions limit some retail convenience, while the product’s extended-release format supports differentiation against immediate-release alternatives.

Key Takeaways

• CLARITIN-D combines loratadine with extended-release pseudoephedrine sulfate in 12-hour and 24-hour tablets.
• The core excipient strategy controls pseudoephedrine release while preserving acceptable loratadine delivery.
• The most valuable formulation know-how concerns polymer architecture, granulation, compression, coating, dissolution, and stability.
• Original active-ingredient exclusivity has expired; current barriers depend on any residual formulation claims, FDA requirements, manufacturing capability, and brand rights.
• No biosimilar pathway applies. Generic, authorized-generic, and private-label competition are the relevant entry mechanisms.
• Excipient suppliers have opportunities in release-control polymers, high-functionality binders, low-moisture systems, lubricant optimization, and protective coatings.
• Pseudoephedrine retail controls make packaging, serialization, inventory management, and pharmacy-channel execution commercially important.
• The strongest commercial entry strategy is a reliable, FDA-compliant extended-release product supported by low-cost manufacturing and retailer-specific packaging.

FAQs

Can CLARITIN-D be reformulated with different excipients?

Yes. A reformulation can use different inactive ingredients, but the sponsor must demonstrate that the change does not adversely affect quality, stability, dissolution, bioavailability, labeling, or therapeutic performance.

Is pseudoephedrine the main formulation challenge in CLARITIN-D?

Yes. Pseudoephedrine is highly water soluble and must be released over the labeled interval. Controlling its release without compromising tablet robustness or loratadine performance is the principal technical challenge.

Does CLARITIN-D require a prescription?

CLARITIN-D is generally sold behind the pharmacy counter in the United States because it contains pseudoephedrine. Retailers must comply with federal and state purchase, identification, recordkeeping, and quantity restrictions.

Can a generic use the same CLARITIN-D excipients?

A generic may use the same inactive ingredients if they are suitable and the formulation meets FDA requirements. Use of the same excipients does not by itself establish therapeutic equivalence or freedom from patent claims.

Are extended-release allergy tablets attractive targets for contract manufacturers?

Yes. The opportunity is strongest for manufacturers with proven modified-release compression, dissolution testing, pseudoephedrine controls, seasonal surge capacity, and retailer-ready packaging operations.

References

1. U.S. Food and Drug Administration. (n.d.). Claritin-D 12 hour: Drug facts and prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Claritin-D 24 hour: Drug facts and prescribing information. DailyMed.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. U.S. Drug Enforcement Administration. (n.d.). Combat Methamphetamine Epidemic Act of 2005 and pseudoephedrine retail requirements. United States Department of Justice.